Congress would like to know why $8 EpiPen sells for $608Staff Writer | October 3, 2016
A congressional committee asked Mylan for additional documentation related to the profitability of EpiPen amid questions about how much taxes the company actually pays on sales of the lifesaving anti-allergy devices.
Pharma A congressional committee wants a lot of information
The letter was sent to Mylan CEO Heather Bresch and suggests the company didn't clearly disclose its tax assumptions for EpiPen when she appeared before the committee last month.
It also suggests that Mylan's current claim about EpiPen's profit doesn't make sense. That's because the company is citing the U.S. tax rate in those profit claims, when Mylan is incorporated overseas and is paying less in taxes.
At the same time, Silicon Valley engineers figure the real cost to make lifesaving auto-injector two-pack is - about $8, The Mercury News reports. ■